Beijing, China, Recently – Gan & Lee Pharmaceuticals, a global leader in biopharmaceuticals (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced the invitation of its CEO, Mr. Du Kai, along with the Latin America regional business team, to a meeting with Mr. Alexandre Padilha, Brazil’s Minister of Health, in Brasília. The two parties conducted thorough discussions focused on enhancing their collaboration in diabetes care, fostering innovation in diagnostic and therapeutic technologies, and exchanging best practices in disease prevention and management. Their goal is to continuously refine diabetes treatment solutions, thereby assisting patients in achieving superior glycemic control and enhanced quality of life.

As a company dedicated to advancing human health, Gan & Lee is committed to fostering innovation for the creation of next-generation diabetes therapies. During the meeting, Mr. Du emphasized the company’s pioneering efforts to improve global accessibility to diabetes care, particularly through its self-developed third-generation insulin analogs, which are delivering transformative value to diverse healthcare systems. Minister Padilha reacted favorably, acknowledging the growing prevalence of diabetes in Brazil and stating   the Ministry of Health’s intention to further strengthen strategic ties with company, aiming to enhance the cost-effectiveness of the national diabetes prevention and treatment infrastructure.

This high-level dialogue is a significant manifestation of Gan & Lee’s internationalization strategy. The company’s products have successfully penetrated key markets in diabetes-burdened countries such as India, Pakistan, Brazil, Indonesia, and Mexico, reaching over 156 million diabetes patients¹. The Brazilian Ministry of Health expressed a strong interest in Gan & Lee’s expertise in biopharmaceutical manufacturing, global supply chain management, and in enhancing medication accessibility. Both parties shared valuable insights on chronic disease prevention and control, committing to collaborate on the development of a comprehensive full-cycle management system for chronic diseases, aimed at enhancing long-term health outcomes for patients.

Reference:

1. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.